Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT(R))

The Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT) method is based on intravenous, sequential administration of a biotinylated antibody, avidin/streptavidin and (90)Y-labelled biotin. The hybridoma clone producing the monoclonal antitenascin antibody BC4, previously used for clinical applic...

Descripción completa

Detalles Bibliográficos
Autores principales: De Santis, R, Anastasi, A M, D'Alessio, V, Pelliccia, A, Albertoni, C, Rosi, A, Leoni, B, Lindstedt, R, Petronzelli, F, Dani, M, Verdoliva, A, Ippolito, A, Campanile, N, Manfredi, V, Esposito, A, Cassani, G, Chinol, M, Paganelli, G, Carminati, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376359/
https://www.ncbi.nlm.nih.gov/pubmed/12671694
http://dx.doi.org/10.1038/sj.bjc.6600818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376359/
https://www.ncbi.nlm.nih.gov/pubmed/12671694
http://dx.doi.org/10.1038/sj.bjc.6600818

Ejemplares similares